- Following last year’s SAFE funding round, Duopharma Biotech delivers a further boost via a Series A funding round of Naluri Hidup to enhance homegrown health-tech
- ‘This is another milestone in Duopharma Biotech’s digital technology journey,’ says Group MD
KUALA LUMPUR, 9 JUNE 2021 – In a new milestone move to boost Malaysia’s digital health growth, Duopharma Biotech Berhad (“Duopharma Biotech” or “the Company”), a leading pharmaceutical company in Malaysia, has agreed to invest into Naluri Hidup Sdn. Bhd. (“Naluri”), a local digital health services provider, via a Series A funding round. Based on this agreement, Naluri will receive a total of USD500,000 from Duopharma Biotech to expand smart digital integrated health applications.
This follows an initial investment of USD250,000 by Duopharma Biotech via a Simple Agreement for Future Equity (“SAFE”) made in April 2020 for a personalised digital holistic healthcare applications. Additionally, Duopharma Biotech, as the returning strategic investor, together with other international and local venture capital firms will enable Naluri, which is a local pioneer in digital therapeutics, to expand operations into the region and deepens its data science capabilities.
This partnership will also enable Duopharma Biotech to deliver evidence-based therapeutic interventions using Naluri’s digital therapeutics solution, which is designed to help people manage their chronic disease risks through structured multi-disciplinary behavioural and psychological coaching programmes. Effective use of holistic therapeutics could double (2x) the healthcare effectiveness when compared to a purely pharmacotherapeutic (medication only) approach, and could also be four times (4X) more cost-efficient and increase accessibilityto clinicians and other health and fitness experts online as well.
Congratulating Naluri on its USD5 million Series A funding round, Duopharma Biotech’s Group Managing Director, Leonard Ariff Abdul Shatar commented: “The smart application of digital technologies to enhance the effectiveness of healthcare and achieve the objective of a healthier life for all is one of Duopharma Biotech’s strategic pillars. We are proud to be part of this latest milestone to empower homegrown health technologies. Indeed, the global coronavirus pandemic has compounded the vital need for concerted co-operative initiatives to promote better health for all.”
Moving ahead, Duopharma Biotech aims to accelerate the use of data science, predictive algorithms, device connectivity and disease monitoring to deliver multiple clinically-significant health outcomes to help patients to get healthier. Duopharma Biotech is already developing various use cases by utilising Naluri’s proprietary technology platform.